Alibaz-Oner F, Kaymaz-Tahra S, Bayındır O, et al. - Comparing TNF inhibitors vs tocilizumab (TCZ) for Takayasu arteritis, similar efficacy and safety outcomes as well as similar drug survival rates seemed to be conferred by TNF inhibitors and by TCZ in patients suffering from Takayasu arteritis.

• This multicenter retrospective cohort study included 111 patients with Takayasu arteritis who were refractory to conventional immunosuppressive drugs and underwent biologic treatment.

• Tocilizumab was administered to 23 patients and TNF inhibitors to 88 patients as first-line biologic agent.

• At 3 ^rd month and at the end of the follow-up, similar complete/partial remission rates were evident between TCZ and TNF inhibitors.

• Both groups had a similar rate of glucocorticoid (GC) dose decrease (≤4 mg) or discontinuation of GCs.

• In TNF inhibitors and in the TCZ group, drug survival rate was 56% and 57%, respectively.

• In terms of relapse, decrease in GC dose, surgery need and mortality, similar outcomes were evident between groups.